Zenosense, Inc. (ZENO) Co-Develops a Super-Bug Detector

Zenosense is a detection device development company based in Valencia, Spain. The company is focused on emerging healthcare technology, specifically, on a device that detects Methicillin-resistant Staphylococcus aureus (MRSA) in hospitals and other healthcare settings.

Founded in 2008, Zenosense was previously known as Braeden Valley Mines and adopted its present name in November of 2013. From the start, the company’s sole aim has been to co-develop an operational MRSA detector (by way of licensed technology) that could be sold to healthcare providers for use in clinical environments.

Zenosense believes there is a huge underlying demand for a cost-effective MRSA detector and that it has identified a lucrative new market segment for a wearable detection device. The costs of MRSA and other hospital-acquired infections to both patients and healthcare providers amount to tens of thousands of invasive infections and deaths as well as billions of dollars in treatments costs, and have spurred Zenosense’s MRSA detection device initiative.

Over the years, MRSA has placed a high financial toll on private and public health care systems, creating a critical issue for healthcare providers and authorities. Early detection of the bug is imperative so that protective actions, such as deep cleaning and ward/patient isolation, can be performed.

Zenosense has an outsourced development model; it has contracted out the development of the device to the Sgenia Group, a known sensor developer with the ability to produce such a sophisticated device. The development of the device started in December 2013 and, should Zenosense successfully co-develop a cost-effective MRSA detector to address the multibillion dollar, and often lethal, MRSA problem, it will likely be extremely attractive to potential distribution partners and end users.

To develop the MRSA device for Zenosense, Sgenia has set up a dedicated subsidiary, Zenon Biosystem. Sgenia already supplies the sensors used in the Tokamak device for important, global nuclear fusion research project. The company also produces an algal contamination detector for use in water supply applications. This detector speedily and successfully scans for unstable organic compounds released by the target algae; a distinctive “chemical signature” that ascertains the presence or absence of the algae. The Sgenia detector is effectively an electronic “nose” that can smell this signature, and Zenon will be using essential elements of this technology platform to develop the MRSA device for Zenosense.

For more information, visit www.zenosense.net

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net